Patients who have migraine often suffer from coexisting issues, such as sleep difficulties, vertigo, and dizziness. A study evaluating the presence of certain symptoms in patients with migraine indicated that some may have a common pathophysiology.
Patients who have migraine often suffer from coexisting issues, such as sleep difficulties, vertigo, and dizziness. According to a new paper published in Pain Medicine, patients with chronic migraine (CM) were more likely to have co-occurring symptoms that affect quality of life than patients with episodic migraine (EM).
The researchers evaluated the presence of certain symptoms in patients with EM and CM and sought to determine the association between these symptoms and Migraine Disability Assessment (MIDAS) scores. Overall, 897 EM patients and 183 CM patients were included in the study.
The authors found that vertigo/dizziness, cutaneous allodynia, concentration-related impairment in function, and abnormal sleep latency were significantly more frequent in patients with CM. These patients also had higher MIDAS and visual analog scale for pain scores.
As for cranial autonomic symptoms (CAS), except for rhinorrhea and facial/forehead sweating, which were more prevalent in patients with CM, there were no significant differences between the 2 groups. Among the overall study population, 69.4% had at least 1 of the CAS and 61.4% had vertigo/dizziness.
The researchers found that abnormal sleep latency and concentration-related impairment in function were more likely to occur in patient groups with CAS, vertigo/dizziness, and cutaneous allodynia than patients without those symptoms.
In a majority (60%) of patients with migraine, it took longer than 30 minutes to fall asleep, and for 16.7% of patients, it took patients longer than 30 minutes more than 3 times a week. Among the CM population, 39.3% had sleep latency longer than 30 minutes more than 3 times a week.
In the overall study population, CAS, vertigo/dizziness, and cutaneous allodynia tended to co-occur.
“One of the most important findings in our study was the coexistence of CAS, vertigo/dizziness, and cutaneous allodynia in patients with migraine,” the authors wrote.
The trigeminovascular system is thought to have a role in CAS. Cortical spreading depression and migraine-related transmitters, such as calcitonin gene-related peptide, explain migraine with vertigo, but experimental studies have now also indicated a possible connection between vestibular and trigeminal nuclei. Finally, cutaneous allodynia is associated with trigeminal nucleus caudalis.
As a result of currently known mechanisms and the co-occurrence of CAS, vertigo/dizziness, and cutaneous allodynia, the authors believe sensitization of trigeminal nuclei may be responsible for generating the symptoms.
“The co-occurrence of CAS, vertigo/dizziness, and cutaneous allodynia in migraine suggests that these symptoms have a common pathophysiology that varies depending on the activation of trigeminal pathways,” the authors concluded.
Reference
Ceylan M, Yalcin A. Coexistence of symptoms associated with trigeminal pathways in chronic and episodic migraine and the effects on quality of life. [published online September 14, 2018.] Pain Med. doi: 10.1093/pm/pny118.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More